You have yet to enroll on this course. To start learning click the button below
Welcome to the SGLT-2 inhibitors course
SGLT-2 inhibitors are one of the newest classes of drug in the diabetes armamentarium. The first module in this course of six modules looks at their history and, through animation, allows you to focus on the physiology and inhibition of renal glucose absorption. The second module builds on this knowledge, allowing you to assess the key trial data to date for empagliflozin, dapagliflozin and canagliflozin. Module 3 compares and contrasts the EMPA-REG OUTCOME and CANVAS Program studies with particular emphasis on cardiovascular outcomes. Module 4 looks at the newer possibilities of this drug class as an adjunct therapy to insulin in type 1 diabetes and highlights the important safety issue of diabetic ketoacidosis. Module 5 focuses on the renal outcomes of major SGLT-2 trials, with particular emphasis on the results of the CREDENCE trial. Finally, Module 6 delves deeper into cardiovascular outcomes from SGLT-2 trials, comparing these with results from the latest large-scale cardiovascular outcomes trial, DECLARE TIMI 58.
Once enrolled on a course you can access the content in any order you wish, simply browse the course using the ‘CONTENT AND YOUR PROGRESS’ section on this page.
If at any time you need help finding the next step to complete just click the green question mark in the bottom right of the screen for directions.